Skip to content

Talk Bio

Actionable Insights Powered by AI

Subscribe
  • Privacy policy
  • Subscribe
  • Home
  • Qualitative Concept
  • Page 38

Qualitative Concept

  • Disease or Syndrome
  • Governmental or Regulatory Activity
  • Intellectual Product

Trump Revokes Biden’s Executive Order on AI Safety and Trustworthiness

8 months ago talkbio0Tagged Administration occupational activities, AI safety, Aortic Valve Insufficiency, Artificial (qualifier value), Biden Executive Order, governance, Regulation, Transplant Registry Unified Management Program

AI Safety, Biden Executive Order, Trump Administration, Artificial Intelligence Governance, AI Regulation

Read More
  • Biologically Active Substance
  • ENTITY
  • Gene or Genome

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

8 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts

Read More
  • ENTITY
  • Functional Concept
  • Health Care Related Organization

AstraZeneca Secures Full FDA Approval for Lymphoma Treatment Selected by CMS

8 months ago talkbio0Tagged Approved, AstraZeneca, CMS-Selected, Lymphoma, United States Food and Drug Administration

AstraZeneca, FDA Approval, Lymphoma Treatment, CMS-Selected

Read More
  • Biologically Active Substance
  • ENTITY
  • Functional Concept

AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma

8 months ago talkbio0Tagged acalabrutinib, Approved, AstraZeneca, BTK gene, Calquence, first-line, Inhibitor, Mantle cell lymphoma, United States Food and Drug Administration

AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval

Read More
  • Disease or Syndrome
  • ENTITY
  • ORG

FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Treatment Options

8 months ago talkbio0Tagged Approved, Crohn 's disease, Eli, Eli Lilly, Inflammatory Bowel Diseases, mirikizumab-mrkz, United States Food and Drug Administration

Omvoh, FDA approval, Crohn’s disease, inflammatory bowel disease, mirikizumab-mrkz, Eli Lilly

Read More
  • Body Location or Region
  • ENTITY
  • Immunologic Factor

OS Therapies Seeks Expedited FDA Approval Following Successful Mid-Stage Osteosarcoma Trial

8 months ago talkbio0Tagged Approved, expedited, mid-stage trial, Oral region, OST-HER2, Osteosarcoma, United States Food and Drug Administration

OS Therapies, FDA approval, osteosarcoma, OST-HER2, mid-stage trial, expedited approval

Read More
  • Amino Acid, Peptide, or Protein
  • Biomedical Occupation or Discipline
  • ENTITY

Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US

8 months ago talkbio0Tagged anti-vaccine, public health medicine (field), sanofi, SmithKline Beecham, Translucent, Urinary hesitation, Vaccines

Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health

Read More
  • ENTITY
  • Health Care Related Organization
  • Manufactured Object

First Lady Jill Biden Continues to Champion Women’s Health Research Beyond White House Tenure

8 months ago talkbio0Tagged ARPA-H, Gender, Health care facility, health research, Healthcare Disparities, Jill, White House Initiative, women 's

Jill Biden, women’s health research, White House Initiative, ARPA-H, healthcare disparities, gender gap in healthcare

Read More
  • Classification
  • ENTITY
  • Functional Concept

Medtronic Launches Adaptive Brain Stimulation for Parkinson’s Disease Following EU Approval

8 months ago talkbio0Tagged adaptive, Approved, BrainSense, CE (Rh group), Deep Brain Stimulation, EU, Massive, Medtronic, Parkinson 's disease

Medtronic, BrainSense, Adaptive Deep Brain Stimulation, Parkinson’s Disease, EU Approval, CE Mark

Read More
  • ENTITY
  • Neoplastic Process
  • ORG

Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding

8 months ago talkbio0Tagged CAR-T, Clearance, Hematologic Neoplasms, in situ, Series, UB-VV111, Umoja Biopharma, United States Food and Drug Administration

Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding

Read More

Posts pagination

Previous 1 … 37 38 39 … 84 Next

Organizations

Agencies amgen AstraZeneca boehringer ingelheim Centers for Disease Control and Prevention (U.S.) Congress (U.S. Legislature) court Drug Industry European Medicines Agency genentech Government Health care facility Johnson and Johnson Moderna Novavax Partnership Pfizer Pharmacy Benefit Manager Pharmacy facility Roche (company) sandoz sanofi squibb United States Federal Trade Commission United States Food and Drug Administration World Health Organization

Concepts & Ideas

Accelerated Accelerated Approval Access accessibility Approved aspects of adverse effects asset Bankruptcy Benefit Capacity Capital Changing Chinese Language Clearance Clinical Data Combined commercial Complete Compound Contract agreement Cost Effectiveness development aspects Discontinuation (procedure) Diversity Dosage drug price Drug Shortage earnings Economic Inflation Effectiveness Efficiency Expectations Failed Failure (biologic function) Financial cost Financial savings financing characteristics Funding Generalized Health Identifier Improvement Increased Infrequent Legal Legal patent Long-term Moderate (severity modifier) New Drug Application Overall Survival Paroxysmal perioperative Phase 2 Phase 3 Prices Pricing Programs - Publication Format Progression-Free Survival Projections and Predictions Recommendation regulatory Review [Publication Type] rights Risk Series Statistical Significance Study on Hold subcutaneous Submission Symptoms aspect Toxicity aspects trends qualifier Variant Weekly

Procedures

Advice Cancer Therapeutic Procedure Cell Therapy Clinical Research Clinical Trials Combined Modality Therapy Confirmatory Trial Detection Drug Discovery Evaluation Gene Modification gene therapy HIV prevention Immunotherapy Injection of therapeutic agent Medical Research activity patient safety Pharmaceutical Services Pharmacotherapy Phase 2 Clinical Trials Phase 3 Clinical Trials Precision Medicine Prescription procedure Reparative closure research Telemedicine Vaccination

Occupations

Artificial Intelligence biology (field) Biotechnology Drug Development Genetic Medicine Global Health Immunology medical technology Neurology speciality Neuroscience discipline public health medicine (field) Science Science of genetics Technology

Disorders

Achondroplasia Acute onset pain Adverse event Amyotrophic Lateral Sclerosis Angioedemas, Hereditary Aortic Valve Insufficiency Asthma Attention deficit hyperactivity disorder Autoimmune Diseases Brain Neoplasms Burning Mouth Syndrome Cardiomyopathies Cardiovascular Diseases Chronic Kidney Diseases Chronic Obstructive Airway Disease Colorectal Carcinoma COVID19 (disease) Dental Plaque Dermatitis, Atopic Diabetes Diabetes Mellitus, Non-Insulin-Dependent Disease Progression Eczema Epilepsy Esophageal Neoplasms Fibrosis Heart failure Hematologic Neoplasms Hemophilia A Hemophilia B Hereditary Diseases Hypoparathyroidism IGA Glomerulonephritis Infantile Severe Myoclonic Epilepsy Inflammation Inflammatory Bowel Diseases Inflammatory disorder Kidney Diseases leukemia Liver and Intrahepatic Biliary Tract Carcinoma Liver diseases Lung diseases Lupus Nephritis Lymphoma, Follicular Malignant neoplasm of breast Malignant neoplasm of endometrium Malignant neoplasm of lung Malignant neoplasm of prostate Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Malignant Neoplasms Malignant tumor of cervix melanoma Mental Depression Mental deterioration Metabolic Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Myeloma Multiple Sclerosis Muscular Dystrophy Muscular Dystrophy, Duchenne Nance-Horan syndrome Narcolepsy Neoplasms Nerve Degeneration nervous system disorder Neurodegenerative Disorders Non-Small Cell Lung Carcinoma Nonalcoholic Steatohepatitis Obesity Paroxysmal nocturnal hemoglobinuria Post-Traumatic Stress Disorder Primary Biliary Cholangitis Psoriasis Pulmonary arterial hypertension Pulmonary Hypertension Reduced Schizophrenia Seizures Severe (severity modifier) Small cell carcinoma of lung Solid Neoplasm Spinal Muscular Atrophy Ulcerative Colitis Urinary tract infection Weight Loss

Objects

Arrowhead Facility (object) Investments Labels (device)

Chemicals & Drugs

Agonist agonists Antibiotics Antibodies Antibodies, Bispecific Antibody-Drug Conjugates Antineoplastic Agents Biological Factors Biosimilars BTK Inhibitor Cancer Vaccines Caplyta Clesrovimab Clustered Regularly Interspaced Short Palindromic Repeats Donanemab Dosage Forms Dupixent durvalumab Enhertu Epidermal Growth Factor Receptor Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide 1 Humira Imfinzi Immunologic Adjuvants Immunostimulating conjugate (antigen) Inhibitor inhibitors Insulin Jemperli Keytruda Lenacapavir Lumateperone Microbicides Midomafetamine Monoclonal Antibodies Mounjaro Nitroglycerin/Sodium Citrate/Ethanol Solution obinutuzumab Ocaliva Opdivo Ozempic patritumab Pediatric brand name pembrolizumab Primary Endpoint Radiopharmaceuticals RNA RNA, Messenger RNA, Small Interfering Rybrevant semaglutide Stelara Tagrisso Tecentriq therapeutic autologous dendritic cells tirzepatide Tremfya Trodelvy Vaccines Wegovy Weight-Loss Agents Zantac

Activities & Behaviors

Acquisition (action) Administration occupational activities Advisory Committees Agreement authorization Automation business career CEO Collaboration competition Continuance of life Drug Approval Industry Leadership Machine Learning Manufacture Mediation Medicare National Security Optimization production Rating (action) Rejection (Psychology) Relations Sales - occupational activity Settlement and Resettlement Success Withdraw (activity)

Geographic Areas

California China Japan Market North Carolina Singapore United States

Phenomena

Emergency Situation Motor function (observable entity) Safety

Living Beings

Adult Child Consumer European (ethnic group) HIV Ira (eukaryote) manager Partner in relationship Pet Animal Plants Plant seeds Respiratory syncytial virus

Anatomy

Cardiovascular system Carvykti Cells Liver Neurosecretory Systems T-Lymphocyte

Physiology

Biological Markers cellular targeting Cessation of life Decision Gene Expression Growth Hearing Immune response Menopause mental health Mutation Practice Experience Response process RNA Interference

Genes & Molecular Sequences

CSHL1 gene K-ras Oncogene PDCD1 gene PREP gene TIGIT gene TYK2 gene
Copyright © TalkBio 2024 Proudly powered by WordPress | Theme: ogma-blog by Mystery Themes.
  • Privacy policy
  • Subscribe